➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
McKinsey
Harvard Business School
McKesson
Johnson and Johnson

Last Updated: June 3, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Gimeracil


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Gimeracil?

Gimeracil is an investigational drug.

There have been 63 clinical trials for Gimeracil. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2016.

The most common disease conditions in clinical trials are Stomach Neoplasms, Pancreatic Neoplasms, and Carcinoma. The leading clinical trial sponsors are Taiho Oncology, Inc., Fudan University, and Quintiles, Inc.

There are one hundred and sixteen US patents protecting this investigational drug and nine hundred and sixty-four international patents.

Recent Clinical Trials for Gimeracil
TitleSponsorPhase
Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic CancerACT GenomicsPhase 2
Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic CancerOno Pharmaceutical Co. LtdPhase 2
Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic CancerTTY BiopharmPhase 2

See all Gimeracil clinical trials

Clinical Trial Summary for Gimeracil

Top disease conditions for Gimeracil
Top clinical trial sponsors for Gimeracil

See all Gimeracil clinical trials

US Patents for Gimeracil

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Gimeracil   Start Trial Metal-salen complex compound, local anesthetic and antineoplastic drug IHI Corporation (Tokyo, JP) Ishikawa; Yoshihiro (Tokyo, JP)   Start Trial
Gimeracil   Start Trial Multimodal silica-based nanoparticles   Start Trial
Gimeracil   Start Trial Device and method for drug evaluation and local treatment Kibur Medical, Inc. (Boston, MA)   Start Trial
Gimeracil   Start Trial Synergistic enhancement of 5-fluorouracil cytotoxicity by deoxyuridine analogs in cancer cells STC.UNM (Albuquerque, NM)   Start Trial
Gimeracil   Start Trial Pharmaceutical compositions comprising POH derivatives NeOnc Technologies, inc. (Los Angeles, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Gimeracil

Drugname Country Document Number Estimated Expiration Related US Patent
Gimeracil China 103781760 2031-06-13   Start Trial
Gimeracil European Patent Office 2738158 2031-06-13   Start Trial
Gimeracil Japan 2013001646 2031-06-13   Start Trial
Gimeracil Japan 5873656 2031-06-13   Start Trial
Gimeracil Russian Federation 2013156414 2031-06-13   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Mallinckrodt
Merck
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.